Clovis Oncology (CLVS) Tops Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Clovis Oncology (CLVS) Tops Q3 EPS by 10c

Clovis Oncology Announces Third Quarter 2020 Operating Results

November 5, 2020 8:05 AM EST

$38.8M in Rubraca® (rucaparib) global sales for Q3 2020; net product revenue up 3% over Q3 2019 Global net product revenue guidance provided for Q4 2020 in a range of $38M to $40M Restructuring U.S. commercial organization to adopt hybrid strategy elevating digital programming and peer-to-peer interactions Oncology pipeline, inclusive of Rubraca, lucitanib and FAP-2286, expected to result in multiple key clinical, development and regulatory milestones during 2021 $224.7M in cash and cash equivalents at September 30, 2020, which is anticipated to fund the Companys operating plan into early... More